VICTORIA SANDLER: Open Payments
NPI 1437820156 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 40 payments from 18 companies in 2025. Trend: 2023 $1,126 · 2024 $916 · 2025 $760
Food & beverage: $760
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $164 |
| Amgen Inc. | 4 | $61 |
| Lilly USA, LLC | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 2 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Merck Sharp & Dohme LLC | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Almatica Pharma LLC | 1 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
Products named: VRAYLAR, FARXIGA, OTEZLA, CAPLYTA, LAGEVRIO, SHINGRIX, Symbravo, LOREEV XR.
Industry payments across DE — which companies pay providers there.
